论文部分内容阅读
目的观察多西紫杉醇联合顺铂二线化疗治疗进展期晚期胃癌患者临床效果。方法选取2012年4月—2016年7月新乡医学院第三附属医院接受氟尿嘧啶和奥沙利铂一线化疗62例进展期晚期胃癌患者,采用随机数字表法分为观察组31例和对照组31例,对照组采用多西紫杉醇进行二线治疗,观察组采用多西紫杉醇联合顺铂进行二线化疗,治疗3 d每周为一个周期,两组均治疗3个周期,比较两组缓解率及不良反应发生情况。采用SPSS18.0统计软件进行统计分析,计量资料用均数±标准差(xˉ±s)表示,采用t检验,计数资料用率(%)表示,采用χ2检验,P<0.05为差异有统计学意义。结果观察组缓解率为74.19%,高于对照组缓解率48.39%,差异有统计学意义(χ2=4.351,P<0.05);观察组血小板降低13例(42.94%)、白细胞减少10例(32.26%)、胃肠道反应16例(51.61%)、肝功能损害3例(9.68%)、心肌损害2例(6.45%)、肾功能损害4例(12.90%)、脱发14例(45.16%)、贫血23例(74.19%),不良反应发生率与对照组10例(32.26%)、9例(9.68%)、14例(45.16%)、4例(12.90%)、1例(3.23%)、3例(9.68%)、15例(48.39%)、21例(67.74%)相比,差异无统计学意义(P>0.05)。结论进展期晚期胃癌采用多西紫杉醇联合顺铂二线化疗治疗,可显著提高治疗效果,安全可靠。
Objective To observe the clinical effect of docetaxel combined with cisplatin in the treatment of advanced advanced gastric cancer. Methods From April 2012 to July 2016, 62 patients with advanced gastric cancer who underwent first-line chemotherapy with fluorouracil and oxaliplatin in the Third Affiliated Hospital of Xinxiang Medical College were divided into observation group (31 cases) and control group (31) by random number table For example, the control group was treated with docetaxel for second-line therapy. The observation group was treated with docetaxel plus cisplatin for second-line chemotherapy. The treatment for one day was weekly for 3 days. Both groups were treated for 3 cycles. The response rate and adverse reactions were compared between the two groups What happened? Statistical analysis was carried out by using SPSS18.0 statistical software. The measurement data were expressed as mean ± standard deviation (x ± s), t test was used and the count data was used (%), using χ2 test, P <0.05 was statistically significant significance. Results The remission rate in the observation group was 74.19%, which was higher than that in the control group (48.39%), the difference was statistically significant (χ2 = 4.351, P <0.05). The observation group had thrombocytopenia in 13 cases (42.94%), leukopenia in 10 cases 16 cases (51.61%) of gastrointestinal reactions, 3 cases of liver dysfunction (9.68%), 2 cases of myocardial damage (6.45%), 4 cases of renal dysfunction (12.90%) and 14 cases of hair loss (45.16% , Anemia in 23 cases (74.19%), the incidence of adverse reactions in the control group, 10 cases (32.26%), 9 cases (9.68%), 14 cases (45.16%), 4 cases (12.90% , 3 cases (9.68%), 15 cases (48.39%) and 21 cases (67.74%), the difference was not statistically significant (P> 0.05). Conclusion advanced gastric cancer with docetaxel combined with cisplatin second-line chemotherapy can significantly improve the treatment effect, safe and reliable.